$103.74 0.00 (%) Incyte Corp - NASDAQ

Jul. 29, 2015 | 04:00 PM

Partner Headlines

  1. What Will Gilead Buy Next? 4 Possible Targets

    IBD | Jul. 15, 2015 | 16:44PM EST
  2. Celgene Hits High As Street Applauds Receptos Buyout

    IBD | Jul. 15, 2015 | 11:12AM EST
  3. Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer

    Benzinga | Jun. 25, 2015 | 07:07AM EST
  4. Benzinga's Top Initiations

    Benzinga | May. 29, 2015 | 09:25AM EST
  5. Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data

    Benzinga | May. 28, 2015 | 13:00PM EST
  6. It's A Big Weekend For Biotech

    Benzinga | Apr. 17, 2015 | 16:31PM EST
  7. Incyte Describes Emerging Development Pipeline Related to Eleven Abstracts at AACR

    Benzinga | Apr. 17, 2015 | 07:39AM EST
  8. Morning Market Gainers

    Benzinga | Feb. 11, 2015 | 09:48AM EST
  9. 10 Biotech Stories You Might've Missed This Week

    Benzinga | Jan. 15, 2015 | 13:18PM EST
  10. Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 1

    Benzinga | Jan. 12, 2015 | 08:55AM EST
  11. 3 Biotech ETFs Rally On Merger News

    Benzinga | Dec. 8, 2014 | 17:43PM EST
  12. 5 Stock-Moving Medtech Events This December

    IBD | Nov. 28, 2014 | 14:18PM EST
  13. Incyte Building Blockbuster Drug One Disease At A Time

    IBD | Nov. 17, 2014 | 15:58PM EST
  14. 1 Biotech Beast Worth Tracking

    Benzinga | Nov. 12, 2014 | 12:08PM EST
  15. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga | Oct. 20, 2014 | 16:58PM EST
  16. UPDATE: Incyte Partners With Genetech to Help With Trials

    Benzinga | Jul. 30, 2014 | 08:43AM EST
  17. Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc.

    GuruFocus | Jun. 9, 2014 | 12:16PM EST
  18. Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN

    GuruFocus | Jun. 8, 2014 | 18:27PM EST
  19. Surges In Biotech Short Interest (INCY, PCYC, RGEN)

    Benzinga | May. 11, 2014 | 16:35PM EST
  20. Mid-Day Losers Mar. 7, 2014: PXLW, ALOG, ALSK, NMRX, NLNK, EMAN

    Benzinga | Mar. 7, 2014 | 11:34AM EST
  21. Morning Movers for Mar. 7, 2014: SKUL, DLIA, BIG, GTAT, CCRN, FL Moving Higher; NLNK, FEYE, SWY, FCEL Lower

    Benzinga | Mar. 7, 2014 | 09:04AM EST
  22. US Stock Futures Edge Higher; All Eyes On Jobs Report

    Benzinga | Mar. 7, 2014 | 07:37AM EST
  23. UPDATE: Bank of America Reinstates Coverage on Incyte on Two Oncology Platforms

    Benzinga | Feb. 26, 2014 | 08:19AM EST
  24. BioMarin Bucks Biotech Short Interest Trend (BIIB, BMRN, MDVN)

    Benzinga | Feb. 13, 2014 | 10:18AM EST
  25. Incyte Q4 swings to a loss

    IBD | Feb. 12, 2014 | 18:43PM EST
  26. Merck soars on cancer deal

    IBD | Feb. 5, 2014 | 18:56PM EST
  27. Merck Q4 Misses, But Cancer Deals Ignite Stock

    IBD | Feb. 5, 2014 | 11:48AM EST
  28. Incyte Names Hervé Hoppenot President and CEO

    Benzinga | Jan. 13, 2014 | 05:49AM EST
  29. Incyte Reports Jakafi Data Continues to Show Improved Overall Survival for Patients with Myelofibrosis at ASH

    Benzinga | Dec. 9, 2013 | 12:48PM EST
  30. UPDATE: Piper Jaffray Initiates Coverage on Incyte as 2014 Biotech Sector Outlook Remains Strong

    Benzinga | Nov. 27, 2013 | 11:16AM EST
  31. Incyte Completes Offering of $750M of Convertible Senior Notes

    Benzinga | Nov. 14, 2013 | 16:15PM EST
  32. Geron Revealed Positive Imetelstat Results Amidst Data Concerns

    Benzinga | Nov. 7, 2013 | 13:10PM EST
  33. Incyte Announces Positive Phase II Clinical Trial Results of Oral JAK1 Inhibitor in Patients with Active RA

    Benzinga | Oct. 28, 2013 | 22:43PM EST
  34. Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor

    Benzinga | Oct. 3, 2013 | 06:03AM EST
  35. Weekly CEO Sells Highlight: ExOne Co, Atmel Corporation, Best Buy and Incyte Corp Ltd.

    GuruFocus | Sep. 22, 2013 | 15:31PM EST
  36. Weekly CFO Sells Highlight: INTU, INCY, RLD, MIDD, XONE

    GuruFocus | Sep. 16, 2013 | 02:05AM EST
  37. UPDATE: Jefferies Raises PT on Incyte Following Favorable Phase 2 RECAP Data

    Benzinga | Aug. 22, 2013 | 11:44AM EST
  38. Incyte surges on drug report

    IBD | Aug. 21, 2013 | 18:43PM EST
  39. Benzinga Market Wrap For August 21: FOMC Minutes Send Markets Spinning

    Benzinga | Aug. 21, 2013 | 16:24PM EST
  40. Mid-Afternoon Market Update: Retailers Hurting As Lowe's Rises

    Benzinga | Aug. 21, 2013 | 15:47PM EST
  41. Mid-Day Market Update: Staples Shares Slip On Weak Earnings

    Benzinga | Aug. 21, 2013 | 12:52PM EST
  42. UPDATE: Canaccord Raises PT on Incyte Following Phase 2 RECAP Data Release

    Benzinga | Aug. 21, 2013 | 11:42AM EST
  43. Incyte Stock Soars As Drug Fights Pancreatic Cancer

    IBD | Aug. 21, 2013 | 11:36AM EST
  44. UPDATE: Bank of America Raises PT on Incyte on Compelling New Data

    Benzinga | Aug. 21, 2013 | 11:31AM EST
  45. Mid-Morning Market Update: Markets Mostly Lower; Lowe's Posts Upbeat Profit

    Benzinga | Aug. 21, 2013 | 10:30AM EST
  46. Stocks Hitting 52-Week Highs

    Benzinga | Aug. 21, 2013 | 10:12AM EST
  47. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 21, 2013 | 08:09AM EST
  48. UPDATE: UBS Investment Research Raises PT on Incyte Following 2Q13 Results

    Benzinga | Aug. 2, 2013 | 11:09AM EST
  49. Mid-Afternoon Market Update: Bernanke Press Conference Leads to Drop in the Markets

    Benzinga | Dec. 12, 2012 | 08:56AM EST
  50. Mid-Day Market Update: Fed to Continue Stimulus, Markets Rise

    Benzinga | Dec. 12, 2012 | 07:26AM EST
Trading Center
×

You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!